Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis
Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes
Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL
Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL